期刊
GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
卷 259, 期 10, 页码 3083-3092出版社
SPRINGER
DOI: 10.1007/s00417-021-05254-5
关键词
Axial length; Children; Efficacy; Low-dose atropine; Myopia; Myopia control
The study found that 0.01% atropine eye drops have a certain effect on slowing down myopia progression in children, especially in inhibiting axial length growth, but the impact on myopic refraction is not significant.
Background Several randomized controlled studies have demonstrated the beneficial effects of 0.01% atropine eye drops on myopia progression in children. However, treatment effects may be different in a routine clinical setting. We performed a retrospective analysis of our clinical data from children to investigate the effect of 0.01% atropine eye drops on myopia progression in a routine clinical setting. Methods Atropine-treated children were asked to instill one drop of 0.01% atropine in each eye every evening at 5 days a week. Myopic children who did not undergo atropine treatment served as controls. Objective refraction and ocular biometry of 80 atropine-treated and 103 untreated children at initial visit and 1 year later were retrospectively analyzed. Results Myopic refractions in the treated and untreated children at initial visit ranged from -0.625 to -15.25 D (-4.21 +/- 2.90 D) and from -0.125 to -9.375 D (-2.92 +/- 1.77 D), respectively. Ages at initial visit ranged from 3.2 to 15.5 years (10.1 +/- 2.7 years) in the treated and from 3.4 to 15.5 years (11.2 +/- 3.0 years) in untreated children. Two-factor ANOVA for age and atropine effects on axial length growth confirmed that axial length growth rates declined with age (p<0.0001) and revealed a significant inhibitory effect of atropine on axial length growth (p<0.0015). The atropine effect on axial length growth averaged to 0.08 mm (28%) inhibition per year. Effects on refraction were not statistically significant. Conclusion The observed atropine effects were not very distinctive: Statistical analysis confirmed that atropine reduced axial length growth, but to an extent of minor clinical relevance. It was also shown that beneficial effects of 0.01% atropine may not be obvious in each single case, which should be communicated with parents and resident ophthalmologists.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据